These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Alemtuzumab with corticosteroid minimization for pediatric deceased donor renal transplantation: a seven-yr experience. Supe-Markovina K; Melquist JJ; Connolly D; DiCarlo HN; Waltzer WC; Fine RN; Darras FS Pediatr Transplant; 2014 Jun; 18(4):363-8. PubMed ID: 24712738 [TBL] [Abstract][Full Text] [Related]
11. The search for the optimal antibody induction strategy in kidney transplantation: still "hazy" after all these years. Stratta RJ Clin Transplant; 2015 Jul; 29(7):569-72. PubMed ID: 25880305 [No Abstract] [Full Text] [Related]
12. Systematic reviews of alemtuzumab in renal transplantation. O'Callaghan JM; Morgan RD; Knight SR; Morris PJ Transpl Immunol; 2013 Mar; 28(2-3):71. PubMed ID: 23352935 [No Abstract] [Full Text] [Related]
17. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance. Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of alemtuzumab in organ transplantation: current clinical status. Ciancio G; Burke GW; Warque ME; Miller J BioDrugs; 2006; 20(2):85-92. PubMed ID: 16626166 [TBL] [Abstract][Full Text] [Related]
19. [HLA-incompatibility and kidney transplant: a question of desensitization]. Grosjean F G Ital Nefrol; 2011; 28(6):581. PubMed ID: 22167608 [No Abstract] [Full Text] [Related]
20. Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death. Plata-Munoz JJ; Vaidya A; Fuggle SV; Friend PJ Transpl Int; 2009 Oct; 22(10):1024-7. PubMed ID: 19624499 [No Abstract] [Full Text] [Related] [Next] [New Search]